Please login to the form below

Not currently logged in
Email:
Password:

Bioniche appoints James Rae as chair

He previously led several Canadian biopharma firms as CEO

Bioniche has named James Rae, CEO of Viron Therapeutics, as chair of its board of directors.

He replaces Graeme McRae at the Canadian company, with McRae retaining his position as CEO and president.

"Mr Rae brings a wealth of sector experience to our board of directors," said McRae. "His knowledge and network will serve the company well as we work to complete important R&D projects and grow revenues."

Rae has a rich pedigree in the Canadian biopharma industry serving as CEO at several companies.

Prior to joining Viron in 2007, he was CEO of Cytochroma, chair and CEO of Resolution pharma, and chair and CEO of Vaxis Therapeutics.

Extending back even further, he also served as president and CEO of Cangene, where he was responsible for restructuring and orchestrating a takeover of the company.

He began his pharma career at Searle, where he spent 18 years, including several as CEO.

Bioniche also announced several changes to its senior management structure, with Cameron Groome, executive VP, corporate & strategic development; Jim Phillips, senior VP, industry relations; Dr Dragan Rogan, chief veterinary scientific officer and Dr Gary Weber, president, Bioniche Food Safety (US) all leaving the company.

Michael Rubin has joined Bioniche, however, as VP, business development.

1st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Brandcast Media

Launched in 2005 and with offices in London and Singapore, Brandcast Media help clients to tell their stories simply and...

Latest intelligence

quantify_messages.png
Meet expert speakers: The right e-detailing content for rich data
We are excited to reveal the names of the expert speakers at Anthill's next webinar "The right e-detailing content for rich data" on the 3rd June 2015, 3 PM GMT+2....
Can rare diseases be a viable option for the pharma industry?
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in...
How do you solve a problem like non-adherence? Part 2
Following her previous piece on patient medical non-adherence, Head of Customer Experience Elisa del Galdo takes a look at the different patient personas that emerge during the diagnosis and treatment...

Infographics